{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:10Z","timestamp":1792602910078,"version":"4.5.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamaoncol.2018.1986","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T14:28:22Z","timestamp":1530887302000},"page":"1228","source":"Crossref","is-referenced-by-count":179,"title":["Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma"],"prefix":"10.1001","volume":"4","author":[{"given":"Maria I.","family":"Carlo","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semanti","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Sloan Kettering Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mandelker","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Vijai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Sloan Kettering Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena","family":"Kemel","sequence":"additional","affiliation":[{"name":"Sloan Kettering Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Knezevic","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Ceyhan-Birsoy","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Cheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almedina","family":"Redzematovic","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devyn T.","family":"Coskey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Stewart","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela G.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Ari","family":"Hakimi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Hyman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ladanyi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Cadoo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia K.","family":"Stadler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Han","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Voss","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Robson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Sloan Kettering Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi180041r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017.","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"coi180041r2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/01.ju.0000132126.85812.7d","article-title":"Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy.","volume":"172","author":"Stephenson","year":"2004","journal-title":"J Urol"},{"issue":"8","key":"coi180041r3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00345-016-1773-y","article-title":"Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study.","volume":"34","author":"Dabestani","year":"2016","journal-title":"World J Urol"},{"issue":"11","key":"coi180041r4","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1101\/gr.131110.111","article-title":"Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics.","volume":"22","author":"Linehan","year":"2012","journal-title":"Genome Res"},{"key":"coi180041r5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fonc.2015.00067","article-title":"Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.","volume":"5","author":"Sankin","year":"2015","journal-title":"Front Oncol"},{"issue":"2","key":"coi180041r6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/(ISSN)1096-9896","article-title":"The Heidelberg classification of renal cell tumours.","volume":"183","author":"Kovacs","year":"1997","journal-title":"J Pathol"},{"issue":"7","key":"coi180041r7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/jama.1995.03520310062031","article-title":"Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer.","volume":"273","author":"Linehan","year":"1995","journal-title":"JAMA"},{"issue":"2","key":"coi180041r8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.juro.2006.09.037","article-title":"Familial renal carcinoma: clinical evaluation, clinical subtypes and risk of renal carcinoma development.","volume":"177","author":"Zbar","year":"2007","journal-title":"J Urol"},{"issue":"7375","key":"coi180041r9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nature10539","article-title":"A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.","volume":"480","author":"Bertolotto","year":"2011","journal-title":"Nature"},{"issue":"3","key":"coi180041r10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/ERC-11-0324","article-title":"Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3.","volume":"19","author":"Malinoc","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"coi180041r11","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas.","volume":"92","author":"Popova","year":"2013","journal-title":"Am J Hum Genet"},{"issue":"1","key":"coi180041r12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1086\/381054","article-title":"Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.","volume":"74","author":"Vanharanta","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"1","key":"coi180041r13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.ejhg.5201904","article-title":"Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.","volume":"16","author":"Pasini","year":"2008","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"coi180041r14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","article-title":"Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management.","volume":"32","author":"Shuch","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi180041r15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/ijc.v100:4","article-title":"A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas.","volume":"100","author":"Gudbjartsson","year":"2002","journal-title":"Int J Cancer"},{"issue":"5","key":"coi180041r16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer.","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"7667","key":"coi180041r17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer.","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"issue":"9","key":"coi180041r18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing.","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"issue":"26","key":"coi180041r19","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer.","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi180041r20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"issue":"32","key":"coi180041r21","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1200\/JCO.2016.67.9084","article-title":"Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma.","volume":"34","author":"Voss","year":"2016","journal-title":"J Clin Oncol"},{"issue":"34","key":"coi180041r22","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.1200\/JCO.2008.18.8821","article-title":"Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.","volume":"27","author":"Gordon","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi180041r23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering\u2013Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology.","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"1","key":"coi180041r24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12920-017-0271-4","article-title":"Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.","volume":"10","author":"Cheng","year":"2017","journal-title":"BMC Med Genomics"},{"issue":"5","key":"coi180041r25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"5","key":"coi180041r26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1053\/j.seminoncol.2016.09.001","article-title":"Genetic predisposition to kidney cancer.","volume":"43","author":"Schmidt","year":"2016","journal-title":"Semin Oncol"},{"issue":"1","key":"coi180041r27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet Med"},{"issue":"9","key":"coi180041r28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations.","volume":"13","author":"Tung","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"coi180041r29","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"coi180041r30","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.7314\/APJCP.2012.13.4.1355","article-title":"The CHEK2 I157T variant and breast cancer susceptibility: a systematic review and meta-analysis.","volume":"13","author":"Liu","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"coi180041r31","article-title":"OncoKB: a precision oncology knowledge base","author":"Chakravarty","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"coi180041r32","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1200\/JCO.2017.35.6_suppl.484","article-title":"Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: correlation between outcome and mutations status in MTOR, TSC1, and TSC2.","volume":"35","author":"Voss","year":"2017","journal-title":"J Clin Oncol"},{"key":"coi180041r33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0959-8049(14)70131-5","article-title":"Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib.","volume":"50","author":"Srinivasan","year":"2014","journal-title":"Eur J Cancer"},{"issue":"22","key":"coi180041r34","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1002\/cncr.v123.22","article-title":"Advances in the diagnosis of hereditary kidney cancer: initial results of a multigene panel test.","volume":"123","author":"Nguyen","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"coi180041r35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaad.2017.01.023","article-title":"Hereditary leiomyomatosis and renal cell cancer syndrome: an update and review.","volume":"77","author":"Patel","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"coi180041r36","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-12-3886","article-title":"Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.","volume":"19","author":"Hakimi","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"coi180041r38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"issue":"1","key":"coi180041r39","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1086\/376435","article-title":"Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.","volume":"73","author":"Toro","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"11","key":"coi180041r40","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/hmg\/ddg148","article-title":"Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency.","volume":"12","author":"Alam","year":"2003","journal-title":"Hum Mol Genet"},{"issue":"1","key":"coi180041r41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12881-017-0436-1","article-title":"Cascade fumarate hydratase mutation screening allows early detection of kidney tumour: a case report.","volume":"18","author":"Chan","year":"2017","journal-title":"BMC Med Genet"},{"issue":"1","key":"coi180041r43","doi-asserted-by":"publisher","first-page":"23.e9","DOI":"10.1016\/j.urolonc.2014.10.014","article-title":"Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.","volume":"33","author":"Ho","year":"2015","journal-title":"Urol Oncol"},{"issue":"6","key":"coi180041r44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"issue":"6","key":"coi180041r46","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene.","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"11","key":"coi180041r47","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","article-title":"Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study.","volume":"34","author":"N\u00e4slund-Koch","year":"2016","journal-title":"J Clin Oncol"},{"key":"coi180041r48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2017.12.022","article-title":"Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.","volume":"92","author":"Star","year":"2018","journal-title":"Eur J Cancer"},{"key":"coi180041r37","volume-title":"GeneReviews(R)","author":"Pithukpakorn","year":"1993-2018"},{"key":"coi180041r42","volume-title":"GeneReviews(R)","author":"Pilarski","year":"1993-2018"},{"key":"coi180041r45","unstructured":"National Comprehensive Cancer Network. Kidney Cancer (Version 1.20184) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed October 30, 2017."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2686813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T16:31:36Z","timestamp":1536856296000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.1986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.1986","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}